Iterum Therapeutics plc: directors' dealings · United States · SEC (Form 4)

About Iterum Therapeutics plc

Iterum Therapeutics plc is a biopharmaceutical company focused on anti-infectives and is listed on the Nasdaq in the United States under the ticker ITRM. For French-speaking investors, it fits the profile of a specialty pharma name with high regulatory sensitivity: the equity story depends on clinical execution, FDA decisions, commercialization milestones, and access to reimbursement rather than on a broad, diversified product portfolio. The company was incorporated in June 2015 under Irish law and later re-registered as a public limited company in March 2018. Its operating footprint is tied to Dublin and Chicago, but its public market listing and commercial opportunity are centered in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1659323/000095017025015857/itrm-20241231.htm?utm_source=openai)) Iterum’s business is built around developing and commercializing anti-infectives designed to address infections caused by multidrug-resistant pathogens in both community and hospital settings. Its lead asset and only marketed product is ORLYNVAH™ (sulopenem etzadroxil and probenecid), an oral penem antibiotic. In October 2024, the FDA approved ORLYNVAH™ for the treatment of uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibacterial treatment options, and the company launched the product commercially in the U.S. in August 2025. Iterum describes ORLYNVAH™ as the first and only approved oral penem antibiotic in the United States, which gives the company a differentiated niche position despite its small scale. ([ir.iterumtx.com](https://ir.iterumtx.com/press-releases/detail/136/iterum-therapeutics-receives-u-s-fda-approval-of?utm_source=openai)) From a competitive standpoint, Iterum is still a small-cap biotech/pharma commercial launch story and remains highly dependent on a single product. Its strategic value comes from the medical need in resistant infections, the limited availability of effective oral options in the uUTI setting, and the regulatory barrier created by FDA approval. The company also highlighted the publication of its REASSURE phase 3 trial in NEJM Evidence, supporting the clinical credibility of oral sulopenem. In 2025, management stated that product revenues were still modest in the early launch phase and that cash resources were intended to fund operations into 2026. ([ir.iterumtx.com](https://ir.iterumtx.com/press-releases/detail/150/iterum-therapeutics-announces-publication-of-reassure-trial?utm_source=openai)) For investors, the key variables are uptake of ORLYNVAH™, prescription growth, payer coverage, sales-force effectiveness, and the company’s ability to extend its cash runway. This is therefore best viewed as a commercialization-stage specialty pharma company rather than a mature diversified antibiotic platform. A major risk factor emerged in March 2026, when the company disclosed that the High Court in Ireland appointed joint liquidators to Iterum Therapeutics plc and Iterum Therapeutics International Limited, a development that materially changes the risk profile and must be factored into any investment view. ([iterumtx.com](https://www.iterumtx.com/?utm_source=openai))